Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (3107)	2/3/2012 11:02:52 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

CYTX is among the few biotechs that have doubled in price so far this year.<g> It has received an IDE approval from the FDA to begin the ATHENA trial. <g>. ATHENA will investigate the use of the Celution System, to prepare adipose-derived stem and regenerative cells to treat chronic myocardial ischemia . (The IDE application was originally submitted to the FDA in December. ). The ATHENA plans to enroll 45 patients with CMI who have limited therapeutic options. It will evaluate a variety of clinical and functional outcomes, including safety, peak oxygen consumption and clinical outcomes at 12-months. CYTX insiders did a good amount of buying late last year and so far this year, seem to just be exercising their options.<g> However, the institutions sold abut 10% of their holdings late last year.<g> CYTX has been burning its cash at a good pace and has substantial LTD. It seems it will need some new cash infusion in the near future. <g> The ACTAY is $4.50 and last year H was $8.44 Next earnings report is expected on March 12. Volume has increased in the last two days and the stock looks overbought near-term as the price is getting too far from its EMA 5 and the RSI climbs above 80 <g> bigcharts.marketwatch.com Bernard